Given that GLP-1R agonists are associated with not only successful weight loss but also glycaemic control, the Endocrine Society has suggested that they can be used as a first-line agent or an add on to other therapies for patients with diabetes [26]. This evidence concerns the gene GLP1R and diabetes mellitus.